Psychemedics Revenue Chart (NASDAQ:PMD)
$20.05 $0.48 (2.45%) PMD stock closing price Aug 22, 2017 (Closing)
The latest 2017-Q2 Psychemedics revenue is 9.68M. Compare Psychemedics revenue chart with AAC Holdings revenue, Quorum Health revenue.
Psychemedics Revenue Chart
You can do annual as well as quarterly comparisons of Psychemedics Corp. net sales with its competitor companies like AAC Holdings, Quorum Health. Over the 5 year period Psychemedics revenue in 2016 was highest at 38.98M. In the latest quarter, PMD revenue 2017-Q2 has changed from 10.21M to 9.68M implying a decrease of 5.19%.
Psychemedics Quarterly Revenue
* Past 5 years Range
|Max PMD Revenue||$11.85M||Sep, 2016|
|Min PMD Revenue||$5.66M||Dec, 2012|
Psychemedics Annual Revenue
* Past 5 years Range
|Max PMD Revenue||$38.98M||Dec, 2016|
|Min PMD Revenue||$25.22M||Dec, 2012|
Psychemedics Annual Revenue VS Peers
|AAC Holdings Revenue||$279.77M||$212.26M||$132.96M||$115.74M||$66.03M|
|Quorum Health Revenue||$2.14B||$2.19B||$2.15B||$1.95B||----|
|Quest Diagnostics Revenue||$7.52B||$7.49B||$7.44B||$7.15B||$7.38B|
|Laboratory Corp. Revenue||$9.64B||$8.68B||$6.01B||$5.81B||$5.67B|
|Enzo Biochem Revenue||$102.77M||$97.59M||$95.94M||$93.7M||$103.08M|
Psychemedics Stock Articles
Revenue or net sales, also called topline or gross income is one of the most important financial metrics used to analyze a company. Revenue is the total amount of money that a company brings in through its various business activities, and appears as the ‘top line’ on the income statement. A company's net sales for a particular period can be found in its income statement. A healthy growth in revenue over time is generally considered good for the company, however other parameters such as profits must also be considered. We can calculate Psychemedics profits by subtracting expenses from Psychemedics revenue. Apart from analyzing a company's revenues over the years, it also helps to compare Psychemedics revenue with peers BioScrip topline, AAC Holdings topline, Quest Diagnostics topline; to see how the company is doing with respect to its peers.